Status:
UNKNOWN
Radiation Therapy in Treating Patients With Non Small Cell Lung Cancer That Has Been Completely Removed by Surgery
Lead Sponsor:
Gustave Roussy, Cancer Campus, Grand Paris
Collaborating Sponsors:
Intergroupe Francophone de Cancerologie Thoracique
The Christie NHS Foundation Trust
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Giving radiation therapy after s...
Detailed Description
OBJECTIVES: Primary * Compare the disease-free survival of patients with completely resected non-small cell lung cancer treated with conformal thoracic radiotherapy vs no radiotherapy. Secondary *...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA :
- Histological evidence of non-small cell lung cancer (NSCLC)
- Complete resection by lobectomy, bilobectomy or pneumonectomy (i.e patients with positive margins) or extra-capsular mediastinal nodal extension breaching the surface of the pathological specimen should not to be included
- Mediastinal lymph node exploration (lymph node sampling or systematic dissection of lymph nodes at stations 2, 4 and 7 in case of upper/middle right-sided lung cancer; 4, 7, 8 and 9 in case of lower right-sided lung cancer; 5, 6 and 7 in case of upper left -sided lung cancer; 7, 8 and 9 in case of lower left-sided lung cancer is recommended)
- Pathologically or cytologically documented N2 mediastinal nodal involvement, at the time of surgery if no preoperative chemotherapy or before preoperative chemotherapy, according to the criteria of the joint AJCC and UICC classification, clinical N2 patients without cytological or histological documentation of mediastinal node involvement before preoperative chemotherapy can be included in the study if and only if, they have histologically confirmed N2 disease at the time of surgery
- Prior chemotherapy is allowed (pre-operative or post-operative adjuvant chemotherapy, or both)
- Patient aged ≥ 18 years
- Good Performance status (WHO ≤ 2)
- Fit enough to receive curative radiotherapy
- Adequate pulmonary function with post-operative FEV1 after surgery \> 1 l or over 35% theoretical value
- Signed informed consent form
- EXCLUSION CRITERIA:
- Documented metastases, (except for ipsilateral nodule(s) in a different lobe after pneumonectomy or bi-lobectomy)
- Major pleural or pericardial effusion
- Synchronous contra-lateral lung cancer
- Clinical progression during post-operative chemotherapy
- Previous chest radiotherapy
- Intention of concomitant chemotherapy during radiotherapy
- Weight loss in the previous 6 months before surgery ≥ 10 %
- Evidence of severe or uncontrolled systemic disease as judged by the investigator
- Recent (\< 6 months) severe cardiac disease (arrhythmia, congestive heart failure, infarction, pace-maker) or pulmonary disease
- Current or past history of neoplasm other than non-small cell lung cancer diagnosed within the last 5 years, except :
- basal cell carcinoma of the skin
- in situ carcinoma of the cervix A patient diagnosed for another neoplasm 5 years ago or more, treated and considered as cured may be included in the study if all the other criteria are respected.
- Pregnancy or breast feeding or inadequate contraceptive measures during treatment
- Patients who, for family, social, geographic or psychological reasons, cannot be adequately followed up and/or are incapable of undergoing regular controls
- Patient deprived of freedom or under guardianship
Exclusion
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2022
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT00410683
Start Date
February 1 2007
End Date
February 1 2022
Last Update
November 20 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Gustave Roussy
Villejuif, Val De Marne, France, 94805